Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr;10(4):1001-1004.
doi: 10.1111/1759-7714.13009. Epub 2019 Feb 27.

Paraneoplastic autoimmunity and small-cell lung cancer: Neurological and serological accompaniments

Affiliations

Paraneoplastic autoimmunity and small-cell lung cancer: Neurological and serological accompaniments

Anastasia Zekeridou et al. Thorac Cancer. 2019 Apr.

Abstract

Paraneoplastic neurological autoimmunity is often associated with small-cell lung cancer (SCLC), a highly malignant neuroendocrine tumor. Paraneoplastic autoimmunity often correlates with longer survival. We describe the paraneoplastic neurological manifestations of patients with SCLC with and without SCLC-predictive autoantibodies and the correlation between autoimmunity and survival. We reviewed the records of 116 patients (51% male) from the Mayo Clinic with histopathologically confirmed SCLC for whom stored serum was available for neural autoantibody testing. Cancer was limited stage in 41%; the median age at diagnosis was 64 years. Paraneoplastic neurological manifestations were recorded in 61% (decreasing frequency: peripheral neuropathy, dysautonomia, cognitive decline, cerebellar ataxia, neuromuscular junction disorder, seizures, cranial neuropathy, movement disorder, brainstem disorder, or myelopathy). Neural autoantibodies, some with pathogenic potential, were detected in the sera of SCLC patients with and without neurological autoimmunity. The most frequent among patients with neurological manifestations were: anti-neuronal nuclear antibody-type 1, voltage-gated calcium channel (VGCC)-N-type, VGCC-P/Q-type, glutamic acid decarboxylase 65 (GAD65), SOX1, and muscle acetylcholine receptor (AChR); while the most common in patients without neurological manifestations were: GAD65, muscle-AChR, and VGCC-P/Q-type. Neither cancer stage at diagnosis nor survival correlated with neurological manifestations or autoantibody-positivity, except for shorter survival in patients with myelopathy. The only predictor of longer survival was limited-stage disease at diagnosis.

Keywords: Anti-Hu antibody; CRMP5 antibody; GABAB receptor antibody; cancer biomarker; paraneoplastic syndrome.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Autoimmune neurological manifestations in 71 patients with small‐ cell lung cancer. (formula image) peripheral neuropathy; (formula image) dysautonomia; (formula image) cognitive decline; (formula image) cerebellar ataxia; (formula image) neuromuscular junction disorders; (formula image) seizures; (formula image) cranial neuropathy; (formula image) movement disorder; (formula image) brainstem manifestations; (formula image) myelopathy; (formula image) psychiatric manifestations; (formula image) opsodonus‐myodonus; (formula image) peripheral nerve hyperexcitability; (formula image) myopathy.

References

    1. Zekeridou A, Griesmann GE, Lennon VA. Mutated cancer autoantigen implicated cause of paraneoplastic myasthenia gravis. Muscle Nerve 2018; 58: 600–4. - PubMed
    1. Gozzard P, Woodhall M, Chapman C et al. Paraneoplastic neurologic disorders in small cell lung carcinoma: A prospective study. Neurology 2015; 85: 235–9. - PMC - PubMed
    1. Maddison P, Gozzard P, Grainge MJ, Lang B. Long‐term survival in paraneoplastic Lambert‐Eaton myasthenic syndrome. Neurology 2017; 88: 1334–9. - PubMed
    1. Gozzard P, Chapman C, Vincent A, Lang B, Maddison P. Novel humoral prognostic markers in small‐cell lung carcinoma: A prospective study. PLoS One 2015; 10: e0143558. - PMC - PubMed
    1. Chen DS, Mellman I. Oncology meets immunology: The cancer‐immunity cycle. Immunity 2013; 39: 1–10. - PubMed